MX354667B - Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas. - Google Patents

Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.

Info

Publication number
MX354667B
MX354667B MX2014003997A MX2014003997A MX354667B MX 354667 B MX354667 B MX 354667B MX 2014003997 A MX2014003997 A MX 2014003997A MX 2014003997 A MX2014003997 A MX 2014003997A MX 354667 B MX354667 B MX 354667B
Authority
MX
Mexico
Prior art keywords
stroke
aminopyridines
methods
treating
sensorimotor impairment
Prior art date
Application number
MX2014003997A
Other languages
English (en)
Other versions
MX2014003997A (es
Inventor
R Blight Andrew
O Caggiano Anthony
J Parry Tom
F Iaci Jennifer
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX2014003997A publication Critical patent/MX2014003997A/es
Publication of MX354667B publication Critical patent/MX354667B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Métodos y composiciones relacionadas con el uso terapéutico de aminopiridinas en pacientes con un impedimento relacionado con un accidente cerebrovascular, en particular, en pacientes con un impedimento sensorial-motriz relacionado con el accidente cerebrovascular.
MX2014003997A 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas. MX354667B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18
PCT/US2012/058607 WO2013052575A1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Publications (2)

Publication Number Publication Date
MX2014003997A MX2014003997A (es) 2014-07-22
MX354667B true MX354667B (es) 2018-03-15

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003997A MX354667B (es) 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.

Country Status (21)

Country Link
US (2) US20130085167A1 (es)
EP (1) EP2766017B1 (es)
JP (1) JP6134722B2 (es)
KR (1) KR20140084120A (es)
CN (2) CN104220072B (es)
AR (1) AR088764A1 (es)
AU (2) AU2012318719B2 (es)
BR (1) BR112014008082A8 (es)
CA (1) CA2850635A1 (es)
CL (1) CL2014000799A1 (es)
CO (1) CO7061067A2 (es)
CR (1) CR20140153A (es)
EA (1) EA029558B1 (es)
HK (2) HK1201204A1 (es)
IL (1) IL231809B (es)
MX (1) MX354667B (es)
SG (2) SG11201401248YA (es)
TW (1) TWI592156B (es)
UA (1) UA114486C2 (es)
WO (1) WO2013052575A1 (es)
ZA (1) ZA201402432B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517856A (ja) * 2013-04-15 2016-06-20 アコルダ セラピュティクス，インコーポレイテッド アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
WO1989009600A1 (en) * 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
DE60034110T2 (de) * 1999-02-09 2007-12-06 The Uab Research Foundation, Birmingham Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US20020022587A1 (en) * 2000-03-28 2002-02-21 Ferguson Alastair V. Methods for effecting neuroprotection
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2108145A4 (en) * 2007-01-26 2011-12-07 Safenet Inc PROTECTING CONFIDENTIAL INFORMATION IN AN INVALIDATE RECIPIENT
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
HK1201204A1 (en) 2015-08-28
CL2014000799A1 (es) 2014-11-03
SG10201600410SA (en) 2016-02-26
EA201490562A1 (ru) 2014-08-29
KR20140084120A (ko) 2014-07-04
CA2850635A1 (en) 2013-04-11
BR112014008082A8 (pt) 2018-01-16
MX2014003997A (es) 2014-07-22
NZ623255A (en) 2016-08-26
IL231809B (en) 2019-06-30
BR112014008082A2 (pt) 2017-07-18
JP6134722B2 (ja) 2017-05-24
AU2018200114A1 (en) 2018-01-25
ZA201402432B (en) 2020-08-26
CN104220072B (zh) 2018-04-17
US20130085167A1 (en) 2013-04-04
IL231809A0 (en) 2014-05-28
UA114486C2 (uk) 2017-06-26
TWI592156B (zh) 2017-07-21
CR20140153A (es) 2014-07-04
WO2013052575A1 (en) 2013-04-11
TW201321000A (zh) 2013-06-01
EP2766017B1 (en) 2020-07-01
HK1204965A1 (en) 2015-12-11
US20160067232A1 (en) 2016-03-10
AU2012318719B2 (en) 2017-10-19
AR088764A1 (es) 2014-07-02
CN104220072A (zh) 2014-12-17
EP2766017A1 (en) 2014-08-20
CN108451953A (zh) 2018-08-28
JP2014531470A (ja) 2014-11-27
AU2012318719A1 (en) 2014-04-17
CO7061067A2 (es) 2014-09-19
EA029558B1 (ru) 2018-04-30
SG11201401248YA (en) 2014-05-29

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PH12018501404A1 (en) Forms of rifaximin and uses thereof
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
IN2015DN02826A (es)
EP2624916A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE OBESE, NEOVASCULARIZATION AND RELATED DISEASES
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
IN2014DN06104A (es)
PH12016500136A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
MX354667B (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
MY174829A (en) Durable treatment with 4-aminopyridine in patients with demyelination
EP2563120A4 (en) METHODS, COMPOSITIONS AND THERAPEUTIC TREATMENT KITS
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
SG10201908587PA (en) Treatment regimens
AU2012240388A8 (en) Treatment regimens
MX362111B (es) Un metodo para mejorar la funcion hepatica.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
UA41936U (ru) Способ лечения крауроза вульвы в детском возрасте
UA104307C2 (ru) Способ продолжительной терапии с применением 4-аминопиридина
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
UA56354U (ru) Способ лечения рецидивирующего дакриоцистита у детей

Legal Events

Date Code Title Description
FG Grant or registration